SLDB
Solid BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
SLDB vs peer average
47/100
SLDB vs. peer average (C vs. C)
Grade spread
A 3 · B 3 · C 1 · D 1 · F 3
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
CAPR is the first available peer comparator.
Capricor is a direct Duchenne operating comparator even though it uses a different modality, because its March 12, 2026 update said deramiocel's BLA was under FDA review with an August 22, 2026 PDUFA date, meaning Solid is also competing for investor attention against a separate late-stage Duchenne asset with nearer regulatory timing.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
SLDB
Solid Biosciences
CAPR
Capricor Therapeutics
Grade
C
B
Momentum
30
64
Value
41
41
Sentiment
79
67
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Mixed
Constructive
Grade position vs CAPR
SLDB / CAPR
Grade Position
In line
SLDB vs. peer average (C vs. C)
47/100
Momentum
30
CAPRValue
41
SLDBSentiment
79
SLDBRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs SLDB
CAPR is the first peer returned for this comparison set.